

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. Contents lists available at ScienceDirect

Vaccine




CrossMark

journal homepage: www.elsevier.com/locate/vaccine

Editorial

Introduction to issue of highlighted research presented at the 2015 National Foundation for Infectious Diseases Annual Conference on Vaccine Research



Vaccines represent one of the most successful public health measures in history. Their development has led to complete elimination of the only human disease ever eradicated, smallpox, as well as eradication of one of the three polio serotypes [1,2]. In the United States alone, routine immunization of children with vaccines against 13 diseases has been estimated to prevent more than 19 million cases of those diseases in each birth cohort, along with averting more than 42,000 deaths [3]. However the development of safe and effective vaccines is required for the many remaining infectious diseases for which vaccines are not available, as well as a counter to the unexpected emergence of new and deadly pathogens. Further, there remains many areas for which existing vaccines have suboptimal effectiveness or safety; characteristics that may be improved upon. Moreover, some vaccines are underutilized and interventions are needed to improve uptake.

The National Foundation for Infectious Diseases (NFID), established in 1973, has a long history in educating the public and healthcare professionals about the causes, prevention, and treatment of infectious diseases. In the mid-late 1990s, Drs. Greg Poland, Bill Martone and Len Novick, then senior leaders with the NFID, put forth a proposal to the NFID Board of Trustees for the formation of a new conference with the goal of creating a scientific forum to bring together the diverse and distinct disciplines that constitute "vaccinology". This vaccine focused conference would be designed to address key challenges to optimizing prevention or treatment of disease through vaccination, and would bring together scientists, public health officials, philanthropic and non-governmental organizations, industry, and healthcare practitioners. Development of this concept was pursued with discussions among individuals at a range of small and large external organizations. Among these, Dr. Regina Rabinovich of the US National Institutes of Health National Institute of Allergy and Infectious Diseases (NIH-NIAID) and Drs. Walter Orenstein and Bruce Weniger at the US Centers for Disease Control and Prevention (CDC) served as key participants in establishing the inaugural conference. This meeting that came to be known as the Annual Conference on Vaccine research (ACVR), was to encompass a broad range of topics related to vaccinology from basic pathogenesis and early vaccine development all the way to

vaccine policy and optimal use to minimize disease burden. Thus, it was distinct from research meetings that were narrowly focused on specific antigens or narrow disease targets, or where vaccinology topics received narrow focus as part of limited sessions at large infectious-disease congresses.

Since the 1st iteration in 1998, ACVRs give persons interested in vaccinology an outstanding opportunity to hear from the world's experts in the field, present their own work, and interact with colleagues with the potential to develop or enhance collaborations. Several major features have defined these meetings. A primary goal has been to welcome papers on all disease targets and research issues, in order to encourage cross-fertilization and communication among researchers and developers of diverse vaccines at the upstream, middle, and downstream ends of the proverbial "vaccine pipeline". Another distinguishing feature has been its semi-didactic nature, in which fully half the 3-day conference is allocated to usually six plenary symposia, for each of which three or four experts deliver invited presentations on a broad range of timely specific topics selected by its planning committee, varying from year to year (Table 1). The remaining half of time is devoted to concurrent oral sessions comprised of papers selected by planning-committee review of unsolicited abstracts submitted by conference attendees. Accepted posters are viewable throughout the three days. The ACVRs have featured participation and major addresses by preeminent vaccinologists, and have thus provided an environment where young researchers can interact with some of the leading and pioneering scientists in the field. The focus on cross-generational interactions is further reinforced by the conferring of awards at the meeting for both early-career young investigators (sponsored by Merck in honor of Dr. Maurice Hilleman) as well as lifetime achievement in vaccinology (sponsored by Sanofi Pasteur in honor of Dr. Charles Mérieux). It is also the usual venue for awarding the Albert B. Sabin Vaccine Institute's Gold Medal for extraordinary contributions in the field of vaccinology or a complementary field.

The 2015 edition of the ACVR well-illustrated the breadth of state of the art in the field of vaccinology, as well as cutting edge science to address some of the problems that have prevented development of safe and effective vaccines against a variety of pathogens and diseases. There were six invited symposia with topics that included: (1) Accelerating Development of Impeded Vaccines, (2) Glycomics in Vaccine Development, (3) New Vaccine Candidates, (4) Innovations in Assessment of Vaccine Efficacy, (5) Immunogen Design and Discovery, and (6) New Vaccines: Beyond Infectious



DOIs of original articles: http://dx.doi.org/10.1016/j.vaccine.2016.03.075, http://dx.doi.org/10.1016/j.vaccine.2015.12.077, http://dx.doi.org/10.1016/j.vaccine.2016.04.083, http://dx.doi.org/10.1016/j.vaccine.2016.03.112

Table 1

Samples of representative symposia topics of the Annual Conferences on Vaccine Research, 1998–2016, each usually featuring three or four invited-expert presenters (*personal communication*, Bruce G. Weniger). Topics are repeated every few years for updates. See www.nfid.org/professional-education/archives/acvr for complete listings.

Approximation 10 A Product of the Constraints Aution y maturation and immune protection 7 d1 (2004) Aution y maturation and immune protection 7 d1 (2004) Aution y maturation and immune protection 7 d1 (2004) Aution y maturation and immune protection 7 d1 (2004) Aution y maturation and immune protection 7 d1 (2004) Aution y maturation and immune protection 7 d1 (2004) Aution y maturation and immune protection 7 d1 (2004) Aution y maturation and immune protection 7 d1 (2004) Aution y maturation and immune protection 7 d1 (2004) Cherical and Add trial design, scorence efficacy 4 d1 (2001), 18 d1 (2015) Combination, multipic chemetry scorences 8 d1 (2005), 18 d1 (2015) Combination, multipic chemetry scorences 8 d1 (2005), 18 d1 (2013), 7 d1 (2014), 12 d1 (2016), 17 d1 (2014) Combination, multipic chemetry scorences 8 d1 (2005), 18 d1 (2013), 7 d1 (2014), 12 d1 (2016), 17 d1 (2014) Combination, multipic chemetry scorences 8 d1 (2005), 12 d1 (2014), 12 d1 (2016), 17 d1 (2014), 12 d1 (2016), 17 d1 (2014), 12 d1 (2016), 12 d1 (2017), 12 d1 (2016), 12 d1 (2016), 12 d1 (2016), 12 d1 (2016)	Symposia topics	ACVR iteration (year)
Addisence vaccines911 (2006)Antipop inscrissing and prevention711 (2004)Antipop inpressing and prevention711 (2004)Antipop inpressing and prevention711 (2004)Bioterrinsin agents, biodefene vaccines, diagent vaccines201 (1998), 411 (2001), 610 (2003)Conserved for the inference vaccines711 (1998), 511 (2001), 511 (2001)Conserved for the inference vaccines711 (1998), 511 (2001), 511 (2001)Conserved for the inference vaccines711 (1998), 511 (2001), 511 (2001), 511 (2001), 511 (2001), 511 (2001), 511 (2001), 511 (2001), 512		
Asitheging unservations and innume potention71/ (2004)Artiging unservations for combating104/ (2004)Astimicrobial rightmane, varcines for combating104/ (2004)Vactions2nd (1999)Vactions2nd (1999)Vactions2nd (1999)Vactions2nd (1999)Vactions2nd (1999)Vactions2nd (1999)Complex vactions8nd (2004)Vactions8nd (2004)Complex vactions8nd (2005)Complex vactions2nd (1999)Complex vactions2nd (1999)Complex vactions8nd (2005)Complex vactions2nd (1999)Complex vactions2nd (1999)Complex vactions8nd (2005)Complex vactions8nd (2005)		
Attaring processing and presentationDarf (1988)Attaring processing vectors101 (2001)Attaring processing vectors201 (1989)Attaring processing vectors201 (1999)Cancer, themic disease, and nun inferious disease variances411 (2001)Cancer, themic disease, and nun inferious disease variances411 (2001)Cancer, themic disease, and nun inferious disease variances411 (2001)Clinical and field vectors201 (1998)Clinical and field vectors114 (2003)Clinical and field vectors114 (2003)Clinical and field vectors114 (2003)Current and realization of disease by vacination114 (2003)Current and realization of disease vacines114 (2003)Current and realization of disease vacines114 (2003)Current and realization of disease vacines114 (2003)Encorrigg and recorriging disease vacines114 (2003)Encorrigg and recorriging disease vacines114 (2003)Encorriging and recorriging disease vacines114 (2003)Encorriging and recorriging disease vacines114 (2003)Clinical and field vector disease pattern research114 (2003)Clinical and field vector disease pattern by vacination610 (2003)Clinical and field vector disease pattern research114 (2001)Clinical and field vectors114 (2001)		
Antimicrobial resistanci, scales for combating1bh (2016)Autor-innualing414 (2001)Autor-innualingKabelines watchines (angerous sensite diseaseAutor-innualing414 (2001), 18h (2001)Cinical and ind developing country200 (1999), 2001, 18h (2015)Cinical and field rail design, watchine (flexey)11 (1999), 5h (2005)Control and rail developing country304 (2000), 18h (2001), 18h (2001)Control and rail developing country304 (2000), 18h (2001), 7h (2004), 12h (2009), 13h (2010), 17h (2014)Control and rail developing country304 (2000), 18h (2003), 7h (2004), 12h (2009), 13h (2010), 17h (2014)Control and rail developing country304 (2000), 18h (2003), 7h (2004), 12h (2009), 13h (2010), 17h (2014)Control and rail developing country304 (2000), 18h (2001), 7h (2004), 12h (2010), 17h (2014)Control and rail developing country304 (2000), 18h (2001), 7h (2004), 12h (2010), 17h (2014)Developing country vaccines, needs, manufacturing, immunization20a (1999), 6h (2003), 7h (2004), 12h (2010), 17h (2014)Developing country vaccines, needs, manufacturing304 (2000)Control and rail developing20a (1998), 6h (2001)Control and rail developing20a (1998), 6h (2001)Control and rail developing country304 (2000), 7h (2004), 14h (2011)Control and rail developing country304 (2000), 7h (2004), 14h (2011), 15h (2015)Control and rail developing country10h (2005), 7h (2004), 14h (2011), 15h (2015)Control and rail developing country10h (2005), 7h (2004), 14h (2011), 15h (2015)Control and rail developing country		
International agents, binderine warches, dangerma evolution disease, and non-infectious disease warches4h (2001), 6th (2003)Cancer, drinnic disease, and non-infectious disease warches4h (2001), 8th (2005)Cancer, drinnic disease, and non-infectious disease warches4h (2001), 8th (2005)Combination, multimetric, chimetri varches1k (1998), 8th (2005)Combination, multimetric, chimetri varches1k (2005)Combination, multimetric, chimetri varches1k (2005)Combination, multimetric, dimetri varches1k (2005)Developing commity varches, meets, manufacturing, immunization1k (2005), 1b (2010), 12th (2010), 12th (2010), 12th (2010), 17th (2014)Technologic, divarches:1k (2005), 1b (2010)Consoliti divarches2kd (2000)Consoliti divarches and immunization - research and1k (2001)Consoliti divarches and immunization - research and5th (2001), 2th (2014), 14th (2011)Cancel divarches2kd (2000)Consoliti divarches and immunization - research and5th (2001)Cancel divarches and immunization - research and5th (2001)Cancel divarches and immunization - research and5th (2002)Cancel divarches and immunization - research and5th (2002)Cancel divarches and immunization - research and5th (2002)Cancel divarches and immunization - research and5th (2001)Cancel divarches and immunization - research and5th (2001)Cancel divarches and immunization - research and5th (2001)Cancel divarches and munization - research and5th (2001)Cancel divarches and munization - re		
vacchsCarser, chronic disese, and non-infections disese vacches4h (2001), 18h (2015)Cinical and field rial design, vacche efficacy11 (1998), 1h (2002), 18h (2015)Conjuntar vacches8h (2005)Conjuntar vacches8h (2005)Debla vacches8h (2005)Debla vacches8h (2005)Economics of vacches in imminization – research and8h (2005)Conjuntar vacche Riso8h (2005)Conjuntar vacches8h (2005)Conjuntar vacche Riso8h (2005)Int Torics I inmunation (the sequel apountario8h (
Lancer, chronic disease, and non-infectiona disease vaccines411 (2001, 18th (2015)Clinical and field edisgon, scalare efficiency2ad (1998)Clinical and relationarie of diseases by vaccination3ad (2000, 18th (2013)Control and scalarian and diseases by vaccination3ad (2000, 18th (2013)Control and scalarian111 (1998), 3th (2003, 7th (2004), 12th (2009), 13th (2010, 17th (2014)Curreness vaccination111 (2008)Developing-control is industry-public health interface111 (2016)Developing-control is industry-public health interface111 (2016)Develo		2nd (1999), 4th (2001), 6th (2003)
Clinical ratis in developing countries14 (1998), Shc (2002, 19th (2015)Combination, multimetric, furmetric varcines14 (1998)Combination, multimetric, furmetric varcines14 (1998)Combination of utoxics version14 (1998)Developing country varcines, medin, manufacturing, immunization14 (2015)Combination of utoxics version60 (2003)Endemination of utoxics version60 (2003)Endemination of utoxics version60 (2003)Combination of utoxics version60 (2003)Combination of utoxics versions14 (2015)Endemination of utoxics versions90 (2006)Combination of utoxics versions90 (2006)Herror furminity, indirect protection90 (2006)Herror furminity, indirect protection90 (2006)Herror furminity, indirect protection90 (2006)Horror fursion inclusions of utoxics versions16 (1998)Horror fursion inclusions of utoxics versions16 (2003)Horror fursion inclusions of utoxics versions <td< td=""><td></td><td>44 (2001) 104 (2015)</td></td<>		44 (2001) 104 (2015)
Clinical trails in developing countries2ad (1999)Combistion, multimetic, chiner, vaccines14 (1990), 14 (2005)Controp and each country accines, enders14 (2005)Controp and each country accines, enders14 (2006), 16 (2013), 17 (12014), 12 (12009), 13 (12010), 17 (12014)Controp and each country accines, enders14 (2008), 16 (2013), 7 (11 (2014), 12 (11 (2009), 13 (11 (2010), 17 (11 (2014)), 12 (11 (2019), 13 (11 (2010), 17 (11 (2014)), 12 (11 (2019), 13 (11 (2010), 17 (11 (2014)), 12 (11 (2019), 13 (11 (2010), 17 (11 (2014)), 12 (11 (2019), 13 (11 (2010), 17 (11 (2014)), 12 (11 (2019), 13 (11 (2010), 17 (11 (2014)), 12 (11 (2019), 13 (11 (2010), 17 (11 (2014)), 12 (11 (2019), 13 (11 (2010), 17 (11 (2014)), 12 (11 (2019), 13 (11 (2010), 17 (11 (2014)), 12 (11 (2019), 13 (11 (2010), 17 (11 (2014)), 12 (11 (2016)), 12 (11		
Combination, multimetic, chimetic varcines1a (1998), 8ht (2005)Control de adlication of desases by varcination3rd (2000, 16th (2013)Control de adlication of desases by varcination3rd (2000, 16th (2013)Developing-controp1th (2005)Developing-controp8th (2015, 19th (2016)Ebola varcines18th (2015, 19th (2016)Ebola varcines18th (2015, 19th (2016)Ebola varcines18th (2015, 19th (2016)Control of varcines: industry-public health interface3rd (2000)Ebola varcines2rd (1990)Control of varcines: industry-public health interface3rd (2000, 17th (2004), 14th (2011)Gottic determinants of mununization - research and6rd (2003)Gottic determinants (1990)5rd (2000, 17th (2004), 14th (2011), 19th (2016)Gottic determinants (1990)11th (2006)Gottic determinants (1990)11th (2006)Gottic determinants (1990)11th (2006)Gottic determinants (1990)11th (2001)Gottic determinants (1990)11th (2001)Gottic and carbohydrides in varcine development18th (2015)Hill Marcines (1990)11th (2006)Human papillomaviros varcines5rd (2002)Human papillomaviros varcines5rd (2002)Human papillomaviros varcines5rd (2002)Human papillomaviros varcines6th (2003)Human papillomaviros varcines5rd (2000)Human papillomaviros varcines5rd (2000)Human papillomaviros varcines6th (2003)Human papillomaviros varcines6th (2003) <td< td=""><td></td><td></td></td<>		
Chrintonia data calacita of disease by vaccination3rd (2000), 16th (2013)Correlates of immunity surcings ready, manufacturing, immunitation1111 (2008)Developing-county vaccines, ends, manufacturing, immunitation11th (2008)technologies, program11th (2008)Construction11th (2008)Construction11th (2008)Construction11th (2008)Construction11th (2008)Construction11th (2001)Construction11th (2001)Construction11th (2001)Construction of vaccine research4th (2001)Construction for vaccine selection11th (2001)Herd Internutivi Natcine development11th (2005)Herd Internutivi Natcine development11th (2006)Herd Internutivi Natcine development11th (2006)Hord Internutivi Natcine development11th (2006)Hord Internutivi Natcine development11th (2006)Hord Internutivi Natcine development11th (2006)Hord Internutivi Natcine development11th (2006)Hor	Combination, multimeric, chimeric vaccines	1st (1998), 8th (2005)
Correlates of immunity. surgate markers1at (1998)Curanous vaccination1ht (2008)Developing-country vaccins, needs, manufacturing, immunization2ad (1998), 6ht (2003), 7ht (2014), 12ht (2016), 13ht (2010), 17ht (2014)Encomption8ht (2015), 19ht (2016)Encomption8ht (2007)Encomption6ht (2003)Encomption6ht (2003)Encomption6ht (2003)Encomption6ht (2003)Center (encomption vaccine Read)6ht (2003)Genetic (encomption vaccine Read)5ht (2016)Genetic (encomption vaccine Read)5ht (2007)Genetic (encomption vaccine Read)5ht (2007)Genetic (encomption vaccine Read)5ht (2007)Genetic (encomption vaccine Read)5ht (2007)Hered Immunity, indirec protection9ht (2006)Hered Immunity, indirec protection9ht (2006)Nutruna pathomes in excarcine9ht (2006)Nutruna pathomes in e		
Cutanow vaccinationInit (2008)Developing-county vaccines, needs, namufacturing, immunization11th (2008), 7th (2004), 12th (2009), 13th (2010), 17th (2014)Economics of vaccines research18th (2015), 19th (2016)Economics for vaccines research18th (2013)Ethics of vaccine research18th (2003), 7th (2004), 14th (2011)Cenetic determinants of immune response2nd (1999)Cenetic determinants of immune response2nd (1999)Hort topics in immunology6th (2003)Hort topics in immunology6th (2003)Hort topics in immunology6th (2003)Immune response: neonates3nd (2000), 9th (2006)Immune response: neonates3nd (2000), 9th (2006)Immune response: neonates3nd (2000), 17th (2014)Immune response: neonates3nd (2		
Developing-country vaccines, needs, namufacturing, immunization2nd (1999), 6th (2003), 7th (2004), 12th (2009), 13th (2010), 17th (2014)Ebola vaccines18th (2015), 19th (2016)Economics of vaccines: industry-public health interface19th (2015)Emerging and remerging disease vaccines19th (2016)Genetic determinants of immunic response2nd (1999)Genetic determinants of immunic response2nd (1999)Genetic determinants of immunic response2nd (1999)Gonomics for vaccines and immunization - research and5th (2002), 7th (2004), 14th (2011)Growins for vaccines9th (2006)Herd immunity, indirect protection9th (2006)Herd immunity, indirect protection9th (2006)Herd immunity, indirect protection9th (2006)Human papillomavirus vaccines5th (2002)Human papillomavirus vaccines5th (2002)Immune response differences: developing vs. developed countries19th (2006)Immune response differences: developing vs. developed countries19th (2005)Immune response: infordation9th (2006)Immune response: infordation9th (2006)Immune response: infordation9th (2007)Immune response: infordation, utilization11th (2008)Immune response: infordation, utilization11th (2008)Immune response: infordation, utilization11th (2007)Immune response: infordation, utilization11th (2007)Immune response: infordation, utilization, emergence, solar11th (2007)Immune response: infordation, utilization, emergence, solar11th (
technologies, programsEconomics of vaccines. industry-public health interface3rd (2000)Energing and revenerging disease vaccines3rd (2003)Epidemiologie effect on disease patterns by vaccination6th (2003)Energing charter search4th (2001)Genetic determinants of innume response2rd (1999)Corbal diameder vaccines1bth (2015)Gorbal diameder vaccines1bth (2015)Growth (2005)1bth (2015)Herd immunity, indirect protection9th (2005)Herd immunity, indirect protection9th (2005)Hotypaties (2005)1bth (2015)Hotypaties (2005)2rd (1999), 5th (2002), 14th (2011), 19th (2016)Hotypaties (2005)1bth (2005)Human paptiformarius vaccine diverloping vaccines9th (2006)Human ersponse: effect of aging1bth (2005)Immune response: effect of aging1bth (2007), 14th (2011)Immune response: effect of aging1bth (2007), 14th (2014), 19th (2016)Immune response: effect of aging1bth (2007), 14th (2014), 15th (2014)Immune response: effect of aging1bth (2007), 14th (2014)Immune response: effect of aging1bth (2007), 14th (2014), 15th (2014)Immune response: effect of aging1bth (2007), 14th (2014), 15th (2014)Immune response: effect of aging1bth (2003), 11bh (2006), 17th (2014), 15th (20		
Ibola vaccinesIsth (2015), 19th (2016)Economics of vaccines industry-public health interface301 (2000)Enterging and remerging disease vaccines19th (2016)Enterging and remerging disease vaccines19th (2016)Enterging and remerging disease vaccines19th (2017)Enterging and research4th (2001)Enterging and research4th (2001)Global aliance for vaccines and immunization - research and5th (2005)Global aliance for vaccines and immunization - research and5th (2005)Global aliance for vaccines991 (2006)Heren Jonusition, fundrec trouted991 (2006)Heren Jonusition, fundrec trouted991 (2006)Heren Jonusition, fundrec trouted991 (2006)Human papilomavirus vaccines5th (2002)Human papilomavirus vaccines991 (2006)Immune response: enenates991 (2000), 17th (2014), 19th (2014)Immune response: enenates991 (2006)Immune response: enenates991 (2006)Immune response: enenates991 (2006)Immune response: enenates991 (2007), 17th (2014), 19th (2014)Immune response: enenates991 (2006)Immune response: enenates991 (2007), 17th (2014), 19th (2014)Immune response: enenates991 (200		2nd (1999), on (2009), on (2001), 12th (2009), 19th (2010), 17th (2011)
Innegring and reemerging disease varcines19h (2016)Epidemiologic effect on discase patterns by varcination64h (2003)Ethics of varcine research40h (2001)Genetic determinants of immune response2nd (1989)Genomics for varcines RAD8th (2002)Genomics for varcines RAD8th (2015)(Jocanit sain detrobuyitatis in varcine development8th (2015)(Jocanit sain detrobuyitatis in varcine development8th (2015)(Jocanit sain development agenda2nd (1999), 5th (2002), 14th (2011), 19th (2016)(Jocanit sain development agenda2nd (1999), 5th (2002), 14th (2011), 19th (2016)(Jocanit sain development agenda2nd (1999), 5th (2002), 14th (2011), 19th (2016)(Jordin sain mechanismis2nd (1999), 5th (2002), 14th (2011), 19th (2016)(Jordin sain mechanismis1st (1998)(Jordin sain mechanismis1st (1998)(Jordin sain mechanismis1st (1998)(Jordin agenda1st (1998)(J		18th (2015), 19th (2016)
Epidemiologic effect on disease patterns by vaccination601 (2003)Cenetic determinants of immune response2nd (1999)Genetic for vaccines and immunization - research and3rd (2000), 7th (2004), 14th (2011)Global allance for vaccines and immunization - research and9th (2005)development agenda9th (2005)Herr immunity, indirect protection9th (2005)Herr immunity, indirect protection9th (2005)Herr immunity, indirect protection9th (2006)Herr immunity, indirect protection9th (2006)Hirr immunity, indirect protection9th (2006)Immune response: effect of agin1st (1998), 3rd (2000), 9th (2006)Immunity, indirect protection, indirection, on ther special population1th (2007), 14th (2011)Immunologic advances, novel strategies, issue9th (2007), 11th (2014), 19th (2015)Immunologic advances, novel strategies, issue9th (2005), 11th (2008), 17th (2014), 19th (2015)Immunologic advances, novel strategies, issue9th (2005), 11th (2008), 11th (2016), 11th (2017), 11th (2014)Immunologic advances, novel strategies, issue9th (2005), 11th (2008), 11th (2016), 11th (2017), 11th (2014)Immunologic advances, novel strategi		
Ethics of vaccine research444 (2001)Cenetic determinants of immunication - research and2nd (1999)Genomics for vaccine R&D3rd (2000, 7th (2004), 14th (2011)Genomics for vaccine ad immunization - research and18th (2015)development agenda18th (2015)Herd immunity, indirect protection9th (2006)Herd immunity, indirect protection9th (2006)Hortopics in immunology6th (2003)Hortopics in immunology6th (2003)Human papiliomavines vaccines5th (2002)Notropics effect of aging1st (1996)Immune response differences: developing vs. developed countries1st (1996)Immunocompromised bots vaccination, other special populations1st (1996)Immunological memory6th (2003), 17th (2014), 19th (2016)Immunological memory1st (1998), 6th (2002), 18th (2010), 17th (2014)Immunological memory1st (1998), 6th (2003), 8th (2005), 12th (2000), 15th (2013)Material munication to protect the fetus and newborn1st (1998), 11th (2006)Material munication to protect the fetus and newborn1st (1998), 11th (2004), 17th (2014), 17th (2014)Material munication to protect the fetus and newborn1st (1998), 11th (2008), 12th (2013), 13th (2012), 15th (2013), 19th (2013), 19th (2013), 19th (2013), 19th (2014), 19th (2015), 19th (2014), 19th (2015), 19th (2014), 19th (2015), 19th		
Genetic determinants of immune responseZnd (1969)Genomics for vaccines and immunization – research and3rd (2000), 7th (2004), 14th (2011)Giobal alliance for vaccines and immunization – research andSth (2022)Genomics for vaccines and immunization – research andSth (2005), 7th (2004), 14th (2011), 19th (2016)Herd immunity, indirect protectionSth (2005), 14th (2011), 19th (2016)Herd immunity, indirect protectionSth (2005), 14th (2011), 19th (2016)Hing pathogen factors, seromolecular epidemiology, natural diseaseTot (2003), 14th (2011), 19th (2016)VectorsTot (2004), 14th (2011), 19th (2016)Immune response differences: developed countriesSth (2003)Immune response differences: developed countriesSth (2006)Immune response: effect of aging1st (1998), 3/d (2000), 9/h (2006)Immune response: effect of aging1st (1998), 3/d (2000), 9/h (2006)Immunologic advances, novel strategies, introduction,6th (2003), 17th (2014), 19th (2016)Immunologic advances, novel strategies, issues8th (2005), 9/h (2006), 17th (2014)Immunologic advances, novel strategies, issues8th (2005), 19/h (2010), 17th (2014)Immunologic advances, novel strategies, issues8th (2002), 10/h (2006), 17th (2014)Immunologic advances, novel strategies, issues8th (2005), 19/h (2010), 17th (2014)Immunologic advances, novel strategies, issues8th (2005), 19/h (2010), 17th (2014)Immunologic advances, novel strategies, issues8th (2005), 19/h (2010), 17th (2014)Immunologic advances, novel strategies, issues8th (2003)Indificences		
Genomics for vaccines and immunization3rd (2000), 7th (2014).Global allances for vaccines and immunization research and development agenda5th (2015)Herd immunity, indirect protection9th (2006).Herd pervisor vaccines and actobs/drates in vaccine development18th (2015).Herd pervisor vaccines and the protection of the pervisor vaccines in immunology.6th (2003).Hot topics in immunology6th (2003).Human papillomavirus vaccines5th (2002).Human papillomavirus vaccines (actobs) genome differences: developing vs. developed countries1st (1996).Immune response: effect daging6th (2003).Immune response: effect daging1st (1996).Immune response: effect daging1st (1996).Immune response: effect daging1st (1996).Immune response: effect daging1st (1996).Immune response: effect daging1st (1996).Immunocompromised basit vaccination, ether special populations1st (1996).Immunological memory1st (1996).Immunological memory1st (1998).Immunological memory1st (1998).Maternal immunization, emergency pandemic vaccines8th (2005).Induces vaccines and immunization, emergency pandemic vaccines8th (2001).Maternal immunization trace development1st (1998).Maternal immuniz		
Clobal alliance for vaccines and immunization – research and development spendaSth (2002)Clyconics and carbohydrates in vaccine development Here immunizity, indirect protectionBth (2015)Herd immunizity, indirect protectionBth (2006)Herd immunizity, indirect protectionBth (2002). 14th (2011), 19th (2016)Hot topics in immunologyBth (2003)Hot topics in immunologyBth (2003)Human papillomavirus vaccinesSth (2002)Immune response: iffect of aging immune response: iffect of aging immunological memoryBth (2006)Immunological memoryBth (2001), 14th (2014), 19th (2016)Immunological memoryBth (2003), 17th (2014), 19th (2016)Immunological memoryBth (2003), 18th (2001), 17th (2014)Madraf vaccines1st (1998), 6th (2003), 13th (2010), 17th (2014)Indirections vaccines and immunization, energency pandenic vaccineBth (2003), 18th (2005), 17th (2014)Madraf vaccines1st (1998), 6th (2003), 18th (2001), 17th (2014)Madraf vaccines1st (1998), 6th (2003), 18th (2005),	*	
Clyconics and carbolydrates in vaccine development18th (2015)Herd immunity, indirect protection9th (2006)Herd immunity, indirect protection2nd (1999), 5th (202), 14th (2011), 19th (2016)HV/ADS vaccines2nd (1999), 5th (202), 14th (2011), 19th (2016)Hott pics in immunology6th (2003)Human papillomavirus vaccines5th (202)Immune evasion mechanisms5th (202)Immune response: differences: developing vs. developed countries9th (2006)Immune response: reforct of aging1st (1998), 3th (2000), 9th (2006)Immune response: reforct of aging1oth (2007), 14th (2011)Immunocompromised host vaccination, other special populations1oth (2007), 14th (2011)Immunological memory5th (2002)Immunological memory5th (2002), 10th (2006), 17th (2014)Immunological memory5th (2002)Madara vaccines8th (2003), 10th (2006), 17th (2014)Immunological memory5th (2002), 10th (2006), 17th (2014)Immunological memory5th (2002), 10th (2006), 17th (2014)Immunological memory5th (2002), 10th (2006), 17th (2014)Madara vaccines1st (1998), 6th (2003), 6th (2013), 12th (2003, 16th (2013), 18th (2012), 18th (2013), 18th (2012), 18th (2014), 19th (2014)Material immunitzation to protect the fetus and newborn1st (1998), 6th (2003), 18th (2004), 12th (2005), 12th (2005), 12th (2005), 12th (2005), 12th (2004), 12th (2004), 12th (2004), 12th (2		
Herd immunity. indirect protection9th (2006)Herpeyritux vaccines14th (2011)HU/ADD vaccines2nd (1999), 5th (2002), 14th (2011), 19th (2016)Hot topics in immunology6th (2003)Human papillomavirus vaccines5th (2002)Immune response: effect of aging9th (2006)Immune response: effect of aging9th (2006)Immune response: effect of aging9th (2006)Immune response: effect of aging1st (1998), 3rd (2000), 9th (2006)Immune response: effect of aging1st (1998), 3rd (2000), 9th (2006)Immune response: effect of aging1st (1998), 3rd (2000), 19th (2016)Immunologic advances, novel strategies, introduction,6th (2003), 17th (2014), 19th (2016)Immunologic advances, novel strategies, issues8th (2003), 17th (2014)Immunologic advances, novel strategies, issues8th (2005), 11th (2011)Immunologic advances, novel strategies, issues8th (2005), 11th (2011)Immunologic advances, novel strategies, issues8th (2003), 11th (2001), 17th (2014)Immunologic advances, novel strategies, issues8th (2003), 11th (2001), 17th (2014)Immunologic advances8th (2003), 11th (2008), 13th (2010), 17th (2014)Malaria vaccines and immunization, emergency pandemic vaccines8th (2003), 11th (2008), 13th (2011), 15th (2013)Maternal immunization to protect the fetus and newborn1st (1998), 6th (2003), 8th (2005), 12th (2004), 15th (2012)Meengevicture vaccines6th (2003)Resputation Vaccines6th (2003)Resputation Vaccines6th (2003)Resputation Vinection vacci		
Hergesvirus vaccines14th (2011)HV/ADS vaccines2nd (1999), 5th (2002), 14th (2011), 19th (2016)Host topics in immunology5th (2002)Human papillomavirus vaccines5th (2002)Immune expose: encorates5th (2002)Immune response: effect of aging,1st (1998), 3th (2000), 9th (2006)Immune response: encorates3th (2000), 9th (2006)Immunocompromised bots vaccination, utilization1th (2005), 17th (2014), 19th (2014)Immunologiz basics for vaccin development5th (2002), 11th (2005), 17th (2014)Immunologiz basics for vaccin development5th (2002), 11th (2006), 17th (2014)Immunologiz basics for vaccin development1st (1998), 6th (2005), 12th (2005), 12th (2004)Mataria vaccines5th (2002), 11th (2006)Immunologiz basics for vaccin development1st (1998), 6th (2005), 12th (2005), 12th (2001, 12th		
HIV/ADS vaccines2nd (1999), 5th (2002), 14th (2011), 19th (2016)Host/pathogen factors, scronelocular epidemiology, natural diseas10th (2006)Hot topiss in immunology6th (2003)Human papillomavirus vaccines5th (2002)Immune response differences; developing vs. developed countries9th (2006)Immune response: effect of aging1st (1998), 3rd (2000), 9th (2006)Immune response: effect of aging1st (1998), 3rd (2000), 9th (2006)Immune response: effect of aging1st (1998), 3rd (2000), 9th (2006)Immuno response: effect of aging1st (1998), 3rd (2000), 9th (2006)Immuno response: enorates3td (2000)Immuno response: enorates5th (2007), 14th (2011)Immunological memory5th (2007), 14th (2011)Immunological memory5th (2002), 17th (2014)Immunological memory5th (2002), 11th (2006), 17th (2014)Inate immunization to protect the fetus and newborn1st (1998), 6th (2003), 8th (2005), 15th (2013), 19th (2016)Maternal immunization to protect the fetus and newborn1st (1998), 10th (2004), 10th (2014)Maternal immunization energence; solution1st (1998), 10th (2005), 10th (2013), 19th (2016)Maternal immunization energence; solution1st (1998), 10th (2004), 17th (2014)Maternal immunization energence; solution1st (1998), 10th (2004), 17th (2014)Maternal immunization energence; solution1st (1998), 10th (2005), 10th (2015), 10th (2016)Meelle-fece vaccines8th (2005), 10th (2013), 19th (2016)Meelle-fece vaccines6th (2003)Regulatory function vaccines7th		
Host (pathogen factors, seromolecular epidemiology, natural disease10th (2005)Wectors6th (2003)Human papillomavirus vascines6th (2003)Immune response: effect of aging5th (2006)Immune response: effect of aging10th (2007), 14th (2016)Immune response: effect of aging10th (2007), 14th (2016)Immunological memory5th (2003), 17th (2014), 19th (2016)Immunological memory5th (2003), 17th (2014), 19th (2016)Immunological memory5th (2003), 11th (2006), 17th (2014)Immunological memory5th (2003), 11th (2006), 17th (2014)Immunological memory5th (2003), 11th (2006), 17th (2014)Immunological memory5th (2003), 11th (2008), 18th (2013), 12th (2009, 16th (2013), 12th (2009, 16th (2013), 12th (2009, 16th (2013), 12th (2009, 16th (2013), 15th (2011)Material immunization to protect the fetus and newborn1st (1998), 6th (2003), 8th (2003), 8th (2003), 12th (2009, 16th (2013), 15th (2016)Melerifee vaccination1st (1998), 5th (2012)Resently-licensed vaccines (fuman papillomavirus, rotavirus, 4-valent1st (1998), 5th (2012)Resplationy infection vaccines5th (2003)Resplationy infection vaccines1st (2000), 1th (2014)Resplationy infection vaccines5th (2002)Resplationy infection vaccines1st (2004), 1th (2014)Resplationy infection vaccines1st (2000	*	
vectorsWetorsSth (2003)Human papillomavirus vaccinesSth (2003)Humane response differences: developing vs. developed countriesSth (2000)Immune response: effect of gaingSth (2000)Immunocompromised host vaccination, other special populationsInth (2007), 14th (2011)Immunological memorySth (2005), 17th (2014), 19th (2014)Immunological memorySth (2002), 17th (2014), 19th (2014)Immunological memorySth (2005), 11th (2006), 17th (2014)Immunological memorySth (2002), 11th (2008), 13th (2010), 17th (2014)Maternal immunization protect the fetus and newbornIst (1998), 10th (2005), 16th (2013), 19th (2016)Meeler-fere vaccinesSth (2003), 15th (2012), 12th (2004)Neseder-fere vaccinesSth (2003), 15th (2012), 12th (2004)Regulatory for vaccinesSth (2003), 15th (2012), 12th (2004), 17th (2014)Regulatory for vaccinesSth (2003), 15th (2012), 12th (2014), 12th (2014), 12th (2015), 12th (2004), 12th (2005), 12th (200		
Human papillomavirus vaccines5th (2002)Immune response differences: developed countries9th (2006)Immune response: effect of aging1st (1998), 3rd (2000), 9th (2006)Immune response: neonates3rd (2000)Immune response: neonates5th (2003), 17th (2014), 19th (2016)Immune response: neonates6th (2007), 14th (2011)Immunocompromised host vaccination, other special populations10th (2007), 14th (2011)Immunological memory5th (2002), 10th (2006)Immunological amenory5th (2002), 10th (2006)Inmunological memory5th (2002), 10th (2006)Inmunological memory5th (2002), 10th (2006)Indiate avaccines and immunization, emergency pandemic vaccines8th (2005), 11th (2008), 17th (2014)Inmunological memory1st (1998), 6th (2003), 8th (2005), 12th (2009, 16th (2013)Mataria vaccines1st (1998), 6th (2003), 8th (2005), 12th (2009, 16th (2013)Material immunization to protect the fetus and newborn1st (1998), 6th (2003), 8th (2005), 15th (2012)Needie-free vaccination1st (1998), 7th (2004)Noscornial Infections vaccines8th (2005)Oral and enteric vaccines8th (2005), 15th (2012)Recently-lensed vaccines (human papillomavirus, rotavirus, 4-valent meningococcal, varcines, gneral, for public health emergencies, for adjivantis3rd (2000), 7th (2004), 7th (2014)Regulation y function vaccines1sth (2003)Regulatory function vaccines1sth (2003)Regulatory function vaccines1sth (2003)Regulatory function vaccines1sth (2003)Regulatory		
Immune exponse.Ist (1998)Immune response. differences:developed countriesImmune response.ffect of agingImmune response.<		6th (2003)
Immune response:9th (2006)Immune response:fit (1998), 3rd (2000). 9th (2006)Immune response:fit (1998), 3rd (2000). 9th (2006)Immune response:fit (1998), 3rd (2000). 9th (2016)Immunological memoryfit (2007). 1th (2014), 19th (2016)Immunological memoryfit (2006)Inmunological memoryfit (2006). 1th (2007). 1th (2014)Immunological memoryfit (2006). 1th (2006)Inducation utilization, emergency pandemic vaccinesfit (2008). 1th (2008). 1th (2011).Inducation vaccines and immunization, emergency pandemic vaccinesfit (2008). 1th (2008). 1th (2008). 1th (2008). 1th (2008).Material immunization to protect the fetus and newbornIst (1998). foth (2006). fit (2013). 1th (2016).Material immunization to protect the fetus and newbornIst (1998). Th (2004).Nesocomial Infections vaccinesfit (2008). Th (2004).Oral and enteric vaccinesfit (2003). Th (2004).Nesocomial Infections vaccinesfit (2003). Th (2004).Nesocomial Infections vaccinesfit (2003).Resputation for tock (furman papillomavirus, otavirus, 4-valentfit (2003).meningococcal, varicella-coster)fit (2003).Resputatory Suppressor T cellsfit (2003).Resputatory Suppressor T cellsfit (2003).Resputatory Suppressor T cellsfit (2004).Novaccinesfit (2003).Sexually-transmitted disease vaccinesfit (2003).Sexually-transmitted disease vaccinesfit (2003).Thatereadis vaccinesfit (2003).Sexually-transmitted disease,	* *	
Immune response: effect of agingIst (1998), 3rd (2000). 9th (2006)Immune response: effect of agingIst (1998), 3rd (2000). 9th (2006)Immunologic advances, novel strategies, istues10th (2007), 14th (2011)Immunologic advances, novel strategies, issues8th (2005). 9th (2006), 17th (2014)Immunologic advances, novel strategies, issues8th (2005), 17th (2014)Immunology basics for vaccine development5th (2002)Influenza vaccines and immunization, emergency pandemic vaccines8th (2005), 17th (2014), 17th (2014)Immark emmunization to protect the fetus and newborn1st (1998), 8th (2005), 12th (2009, 16th (2013)Material immunization to protect the fetus and newborn1st (1998), 8th (2005), 12th (2009, 16th (2013)Material immunization to protect the fetus and newborn1st (1998), 7th (2014)Material immunization to protect the fetus and newborn1st (1998), 7th (2004)Noscomial Infections vaccines6th (2003)Recell-free vaccination1st (1998), 7th (2014)Needle-free vaccines8th (2005), 15th (2012)Recently-licensed vaccines (human papillomavirus, rotavirus, 4-valent meningococcal, varicella-zoster)3rd (2000), 7th (2014), 17th (2014)Regulatory finefction vaccines3rd (2000), 7th (2004), 15th (2013)Resplatory infection vaccines3rd (2000), 7th (2004), 15th (2013)Resplatory superseor T cells6th (2003)Resultary/Suppressor T cells6th (2003)Rever acute respiratory syndrome/coronavirus vaccines3rd (2000)Strate development: new and innovative approaches, immunogens, impeded vaccines3rd (2000)<		
Immune response: neonates3rd (2000)Immunization programs, policies, strategies, introduction, implementation, utilization3rd (2000), 17th (2014), 19th (2016)Immunological memory10th (2007), 14th (2011)Immunological memory10th (2005), 14th (2010), 17th (2014)Immunological memory5th (2002), 10th (2006)Influenza vaccines and immunization, emergency pandemic vaccines5th (2002)India vaccines5th (2002)Maternal immunization to protect the fetus and newborn1st (1998), 6th (2003), 18th (2010), 17th (2014)Maternal immunization to protect the fetus and newborn1st (1998), 10th (2006), 16th (2013), 19th (2016)Maternal immunization to protect the fetus and newborn1st (1998), 10th (2006), 16th (2013), 19th (2016)Meedle-free vaccination1st (1998), 7th (2014)Nosocomial Infections vaccines6th (2003)Oral and enteric vaccines7td (2000), 7th (2004), 17th (2014)Menningcocccal, varicella-zostery8th (2005), 15th (2012)Resplatory/Suppresor T cells6th (2003)Resplatory/Suppresor T cells6th (2003)Resultarior vaccines1st (1998), 9th (2005)SARS (severe acute respiratory syndrome)/coronavirus vaccines3rd (2000), 16th (2013)SARS (severe acute respiratory syndrome)/coronavirus vaccines2nd (1999), 9th (2005)Tuberculosis vaccines2nd (1999), 9th (2005)Tuberculosis vaccines2nd (1999), 9th (2005)Tuberculosis vaccines2nd (1999), 9th (2005)Tuberculosis vaccines2nd (1999), 9th (2005)Naccines devolopment: new and innovative		
Immunization programs, policies, strategies, introduction, implementation, utilization6th (2003), 17th (2014), 19th (2016)Immunologic advances, novel strategies, issues8th (2005), 9th (2006), 17th (2014)Immunologic advances, novel strategies, issues8th (2005), 0th (2006), 17th (2014)Immunology basics for vaccine development5th (2002), 10th (2006), 13th (2010), 17th (2014)Influenza vaccines and immunization, emergency pandemic vaccines8th (2005), 11th (2008), 13th (2010), 17th (2014)Malaria vaccines8th (2005), 16th (2003), 8th (2005), 12th (2009, 16th (2013))Maternal immunization to protect the fetus and newborn1st (1998), 10th (2006), 16th (2013), 19th (2016)Meterla immunization to protect the fetus and newborn1st (1998), 10th (2006), 16th (2013), 19th (2016)Meterla immonization vaccines8th (2003)Needle-free vaccination1st (1998), 7th (2014)Noscocral varcicels8th (2005), 15th (2012)Regulation of vaccines, general, for public health emergencies, for adjuvants3rd (2000), 16th (2013)Regulation of vaccines9rd (2000), 16th (2013)Regulation of vaccines9rd (2000), 16th (2013)Regulation vaccines3rd (2000), 16th (2013)Regulation vaccines3rd (2000), 16th (2013)Regulation vaccines9rd (2000), 16th (2013)Regulation vaccines3rd (2000), 16th (2013)Regulat		
Immunocompromised host vaccination, other special populations10th (2007), 14th (2011)Immunological memorySth (2002), 10th (2006)Immunological memorySth (2002), 10th (2006)Immunological memorySth (2002), 10th (2006)Influenza vaccines and immunization, emergency pandemic vaccinesSth (2002), 11th (2008), 13th (2010), 17th (2014)Influenza vaccines and immunization, emergency pandemic vaccinesSth (2003), 11th (2008), 13th (2010), 17th (2014)Malaria vaccinesIst (1998), 6th (2003), 8th (2003), 12th (2009, 16th (2013)Maternal immunization to protect the fetus and newbornIst (1998), 10th (2006), 16th (2013), 19th (2016)Meedle-free vaccinationIst (1998), 10th (2006), 16th (2013), 19th (2016)Needle-free vaccinationIst (1998), 10th (2006), 16th (2013)Oral and enteric vaccines6th (2003)Recently-licensed vaccines (human papillomavirus, rotavirus, 4-valent meningococcal, varicella-zoster)11th (2008)Regulation of vaccines, general, for public health emergencies, for adjuvants3rd (2000), 7th (2004), 17th (2014)Respiratory infection vaccines6th (2003)SABS (severe acut respiratory syndrome)/coronavirus vaccines7th (2004)SABS (severe acut respiratory syndrome)/coronavirus vaccines7th (2004)Substrustive acutes7th (2004)Substrust		
Immunologic advances, novel strategies, issues8th (2005, 9th (2006), 17th (2014)Immunological memory5th (2002), 10th (2006)Inmunological memory5th (2002), 10th (2006)Influenza vaccines and immunization, emergency pandemic vaccines8th (2005, 11th (2008), 13th (2010), 17th (2014)Malaria vaccines1st (1998), 10th (2006), 16th (2013), 19th (2013)Maternal immunization to protect the fetus and newborn1st (1998), 10th (2006), 16th (2013), 19th (2016)Meningococcal vaccines4th (2001)Needle-free vaccination1st (1998), 10th (2006), 16th (2013), 19th (2016)Nesocomial Infections vaccines6th (2003)Oral and enteric vaccines (human papillomavirus, oravirus, 4-valent11th (2008)meningococcal, varicella-zoster)8th (2000), 17th (2004), 17th (2014)Recently-licensed vaccines (human papillomavirus, rotavirus, 4-valent11th (2008)meningococcal, varicella-zoster)3rd (2000), 7th (2004), 17th (2014)Regulatory/Suppressor T cells6th (2003)Respiratory infection vaccines3rd (2000), 16th (2013)Rotavirus vaccines7th (2004), 17th (2014)SARS (severe acute respiratory syndrome)/coronavirus vaccines7th (2004), 17th (2014)Saka (severe acute respiratory syndrome)/coronavirus vaccines7th (2004), 16th (2013)Vaccines2nd (1999), 8th (2005)Tuberculosi vaccines2nd (1999), 8th (2005), 12th (2009), 16th (2013), 15th (2012), 16th (2013), 15th (2014), 15th (2012), 16th (2013), 15th (2003), 8th (2005)Vaccine shortages and supply4th (2001), 9th (2006), 12th (2009), 15th (2012), 16th (2013), 15th (2003), 8th (
Immunological memorySth (2002, 10th (2006)Immunology basics for vaccine development5th (2002, 10th (2006)Influenza vaccines and immunization, emergency pandemic vaccines8th (2005, 11th (2008), 13th (2010), 17th (2014)Inataria vaccines1st (1998), 6th (2003), 8th (2005), 12th (2009, 16th (2013)Maternal immunization to protect the fetus and newborn1st (1998), 10th (2006), 16th (2013), 19th (2016)Meternal immunization to protect the fetus and newborn1st (1998), 10th (2006), 16th (2013), 19th (2016)Meedle-free vaccination1st (1998), 7th (2004)Noscocmial Infections vaccines6th (2003)Recently-licensed vaccines (human papillomavirus, rotavirus, 4-valent11th (2008)meningococcal, varicella-zoster)8th (2000), 7th (2004), 17th (2014)Regulation of vaccines, general, for public health emergencies, for adjuvants3rd (2000), 7th (2004), 17th (2014)Regulatory/Suppressor T cells6th (2003)Respiratory infection vaccines3rd (2000), 7th (2014), 17th (2014)SKS vaccines15th (2012)SkS vaccines6th (2003)SkS (severe acute respiratory syndrome)/coronavirus vaccines3rd (2000), 16th (2013)SkS (severe acute respiratory syndrome)/coronavirus vaccines3rd (2000)Therapeutic vaccines2nd (1999), 8th (2005), 12th (2009), 16th (2013)Vaccine edvelopment: new and innovative approaches, immunogens, vaccines shet surveillance and research4th (2001), 9th (2005), 12th (2009), 15th (2012), 16th (2013), 17th (2014), 18th (2015)Vaccine shortages and supply6th (2003), 8th (2005)Vaccine shortages and sup		
Immunology basics for vaccine development5th (2002)Influenza vaccines and immunization, emergency pandemic vaccines8th (2005), 11th (2008), 13th (2010), 17th (2014)Inate immunity3rd (2000, 11th (2008)Malaria vaccines1st (1998), 10th (2006), 16th (2013), 19th (2016)Maternal immunization to protect the fetus and newborn1st (1998), 10th (2006), 16th (2013), 19th (2016)Meningcoccal vaccines4th (2001)Needle-free vaccination1st (1998), 17th (2004)Noscoronial Infections vaccines6th (2003)Oral and enteric vaccines8th (2005), 15th (2012)Recently-licensed vaccines (human papillomavirus, rotavirus, 4-valent11th (2008)meningcoccal, varicella-zoster)3rd (2000), 7th (2004), 17th (2014)Regulatory fuppressor T cells6th (2003)Regulatory fuppressor T cells6th (2003)Regulatory fuppressor T cells6th (2003)Socries3rd (2000)Socries5th (2002)RSV vaccines6th (2003)SARS (severe acute respiratory syndrome)/coronavirus vaccines7th (2004)Socries2nd (1999), 9th (2006), 12th (2009), 16th (2013)Vaccine development: new and innovative approaches, immunogens, vaccines further vaccines3rd (2000)Tuberculosis vaccines2nd (1999), 9th (2006), 12th (2009), 15th (2012), 16th (2013), 17th (2014), 18th (2015)Vaccine short ges and supply6th (2003), 8th (2005)Vaccine short ges and supply6th (2003), 8th (2005), 12th (2009), 15th (2012, 16th (2013), 17th (2014), 18th (2015)Vaccine short ges and supply6th (2003), 8th (2005)		
Influenza vaccines and immunization, emergency pandemic vaccines8th (2005), 13th (2010), 17th (2014)Innate immunity3rd (2000, 11th (2008), 13th (2005), 12th (2009, 16th (2013))Mataria vaccines1st (1998), 6th (2003), 8th (2005), 12th (2009, 16th (2013))Maternal immunization to protect the fetus and newborn1st (1998), 10th (2006), 16th (2013), 19th (2016)Meningococcal vaccines4th (2001)Needle-free vaccination1st (1998), 7th (2004)Noscomial Infections vaccines6th (2003)Oral and enteric vaccines6th (2003)Recently-licensed vaccines (human papillomavirus, rotavirus, 4-valent meningococcal, varicella-zoster)3rd (2000), 7th (2004), 17th (2014)Regulatory/Suppressor T cells6th (2003)Respiratory infection vaccines3rd (2000), 7th (2014)SKS (severe acute respiratory syndrome)/coronavirus vaccines7th (2004)Sexually-transmitted disease vaccines7th (2004)Sexually-transmitted disease vaccines7th (2004)Vaccine evelopment: new and innovative approaches, immunogens, vaccines sent, stechnologies, strategies, alternative animal models, impeded vaccines2nd (1999), 8th (2005)Vaccine safety surveillance and research4th (2001), 15th (2002), 10th (2009), 15th (2011), 15th (2012), 16th (2013), 17th (2014), 18th (2005)Vaccine safety surveillance and comparative models of disease and protection, synergies with human vaccine development, One Health Veterinary vaccines for zononic diseases, economically important for animals, conservation medicine, differentiating infected5th (2003), 9th (2006), 13th (2010), 15th (2012)		
Innate immunity3rd (2000, 11th (2008)Malaria vaccines1st (1998), 6th (2003), 8th (2005), 12th (2009, 16th (2013)Maternal immunization to protect the fetus and newborn1st (1998), 10th (2006), 16th (2013), 19th (2016)Meningococcal vaccines4th (2001)Needle-free vaccination1st (1998), 7th (2004)Nosocomial Infections vaccines6th (2003)Oral and enteric vaccines8th (2005), 15th (2012)Recently-licensed vaccines (human papillomavirus, rotavirus, 4-valent meningococcal, varicella-zoster)11th (2008)Regulation of vaccines, general, for public health emergencies, for adjuvants3rd (2000), 7th (2004), 17th (2014)Regulatory/Suppressor T cells6th (2003)Regulatory infection vaccines3rd (2000), 16th (2013)Respiratory infection vaccines15th (2012)RSV vaccines6th (2003)SARS (severe acute respiratory syndrome)/coronavirus vaccines7th (2004)Sexually-transmitted disease vaccines7th (2004)Vaccine development, new and innovative approaches, immunogens, vaccines trends, technologies, strategies, alternative animal models, impeded vaccines1th (2006), 12th (2009), 15th (2012), 16th (2013), th (2001), 15th (2012), 16th (2013), th (2011), 15th (2012), 16th (2013), th (2014), 12th (2009), 15th (2012), 15th (2012), 16th (2013), th (2005), 12th (2009), 15th (2012), 16th (2013), th (2005), 12th (2009), 15th (2012), 16th (2013), th (2005), 12th (2009), 15th (2012), 16th (2013), th (2014), 18th (2015)Vaccine selective respiratory wordels of disease and impeded vaccines1th (2006), 12th (2009), 15th (2012), 15th (2012), 15th (2012), 15th (2012), 15th (20		
Maternal immunization to protect the fetus and newborn1st (1998), 10th (2006), 16th (2013), 19th (2016)Meningococcal varcines4th (2001)Nosocomial Infections vaccines6th (2003)Oral and enteric vaccines (human papillomavirus, rotavirus, 4-valent meningococcal, varicella-zoster)1th (2008)Recently-licensed vaccines (human papillomavirus, rotavirus, 4-valent meningococcal, varicella-zoster)3rd (2000), 7th (2004), 17th (2014)Regulation of vaccines, general, for public health emergencies, for adjuvants3rd (2000), 7th (2004), 17th (2014)Regulatiory/Suppressor T cells6th (2003)Respiratory infection vaccines3rd (2000), 16th (2013)Rotavirus vaccines15th (2012)Rotavirus vaccines6th (2003)SARS (severe acute respiratory syndrome)/coronavirus vaccines7th (2004)Sexually-transmitted disease vaccines3rd (2000)Therapeutic vaccines2nd (1999), 8th (2005)Tuberculosis vaccines2nd (1999), 9th (2006), 12th (2009), 16th (2013)Vaccine development: new and innovative approaches, immunogens, impeded vaccines4th (2001), 9th (2006), 12th (2009), 15th (2012), 16th (2013), 4th (2011), 15th (2012), 16th (2013), 4th (2011), 15th (2012), 16th (2013), 4th (2011), 9th (2006), 12th (2009), 15th (2012)Vaccine shortages and supply6th (2003), 8th (2005)Vaccine shortages and supply6th (2003), 8th (2005), 1st (1998), 8th (2005), 1st (2012), 16th (2013), 4th (2011), 15th (2012), 16th (2013), 4th (2011), 15th (2012), 16th (2013), 4th (2011), 15th (2012), 16th (2013), 1st (1998), 8th (2005), 1st (1998), 8th (2005), 12th (2009), 15th (2012), 16th (2013), 	Innate immunity	
Meningococcal vaccines4th (2001)Needle-free vaccination1st (1998), 7th (2004)Nosocomial Infections vaccines6th (2003)Oral and enteric vaccines8th (2005), 15th (2012)Recently-licensed vaccines (human papillomavirus, rotavirus, 4-valent11th (2008)meningococcal, varicella-zoster)3rd (2000), 7th (2004), 17th (2014)Regulation of vaccines, general, for public health emergencies, for adjuvants3rd (2000), 7th (2004), 17th (2014)Regulatory/Suppressor T cells6th (2003)Respiratory infection vaccines3rd (2000), 16th (2013)Rotavirus vaccines6th (2003)Rotavirus vaccines6th (2003)SARS (severe acute respiratory syndrome)/coronavirus vaccines7th (2004)Sexually-transmitted disease vaccines2nd (1999), 8th (2005)Tuberculosis vaccines2nd (1999), 9th (2006), 12th (2001), 14th (2011), 15th (2012), 16th (2013),Vaccine development: new and innovative approaches, immunogens, impeded vaccines4th (2001), 5th (2002), 10th (2006), 13th (2010), 14th (2011), 15th (2012), 16th (2013),Vaccine safety surveillance and research4th (2001), 9th (2006), 12th (2009), 15th (2012), 16th (2013),Vaccine safety surveillance and research4th (2003), 8th (2005)Vaccine shortages and supply6th (2003), 9th (2006), 12th (2009), 15th (2012), 15th (2012), 15th (2012),Vaccine shortages and comparative models of disease and protection, synergies with human vaccine development, One Health Veterinary vaccines for zoonotic diseases, economically important food animals, conservation medicine, differentiating infected from5th (2002), 6th (2003), 9th (
Needle-free vaccination1st (1998), 7th (2004)Nosocomial Infections vaccines6th (2003)Oral and enteric vaccines (human papillomavirus, rotavirus, 4-valent meningococcal, varicella-zoster)11th (2008)Regulation of vaccines, general, for public health emergencies, for adjuvants3rd (2000), 7th (2004), 17th (2014)Regulatory/Suppressor T cells6th (2003)Respiratory infection vaccines3rd (2000), 16th (2013)Rotavirus vaccines6th (2003)Respiratory infection vaccines6th (2003)SRSV vaccines6th (2003)SKS (severe acute respiratory syndrome)/coronavirus vaccines7th (2004)Sexually-transmitted disease vaccines7th (2004)Sexually-transmitted disease vaccines7th (2004)Tuberculosis vaccines2nd (1999), 8th (2005)Tuberculosis vaccines2nd (1999), 9th (2006), 12th (2013), 14th (2011), 15th (2012), 16th (2013),Vaccine after surveillance and research4th (2011), 9th (2006), 12th (2009), 15th (2012), 16th (2013),Vaccine adveclops2nd (1999), 8th (2005)Vaccine shortages and supply6th (2003), 8th (2005)Vaccines for zoonotic diseases, economically important for danimals, conservation medicine, differentiating infected from5th (2002), 6th (2003), 9th (2006), 13th (2010), 15th (2012)		
Nosocomial Infections vaccines6th (2003)Oral and enteric vaccines6th (2003)Recently-licensed vaccines (human papillomavirus, rotavirus, 4-valent meningococcal, varicella-zoster)11th (2008)Regulation of vaccines, general, for public health emergencies, for adjuvants3rd (2000), 7th (2004), 17th (2014)Regulatory/Suppressor T cells6th (2003)Respiratory infection vaccines3rd (2000), 16th (2013)Rotavirus vaccines6th (2003)SARS (severe acute respiratory syndrome)/coronavirus vaccines7th (2004)Sexually-transmitted disease vaccines7th (2004)Sexually-transmitted disease vaccines2nd (1999), 8th (2005)Tuberculosis vaccines, impeded vaccines2nd (1999), 9th (2006), 12th (2009), 16th (2013)Vaccine soft generation4th (2001), 15th (2012), 16th (2013), 17th (2011), 15th (2012), 16th (2013), 17th (2014), 18th (2005), 12th (2005), 12th (2009), 16th (2013), 17th (2014), 18th (2005), 12th (2005), 12th (2009), 16th (2011), 15th (2012), 16th (2013), 17th (2014), 18th (2005), 12th (2005), 12th (2005), 12th (2005), 12th (2005), 12th (2014), 18th (2015), 15th (2012), 16th (2013), 17th (2014), 18th (2005), 12th		
Oral and enteric vaccines8th (2005), 15th (2012)Recently-Licensed vaccines (human papillomavirus, rotavirus, 4-valent meningococcal, varicella-zoster)11th (2008)Regulation of vaccines, general, for public health emergencies, for adjuvants3rd (2000), 7th (2004), 17th (2014)Regulatory/Suppressor T cells6th (2003)Respiratory infection vaccines3rd (2000), 16th (2013)Rotavirus vaccines15th (2012)Rotavirus vaccines6th (2003)SARS (severe acute respiratory syndrome)/coronavirus vaccines3rd (2000)Sexually-transmitted disease vaccines3rd (2000)Therapeutic vaccines2nd (1999), 8th (2005)Tuberculosis vaccines2nd (1999), 9th (2006), 12th (2009), 16th (2013)Vaccine development: new and innovative approaches, immunogens, vaccines, trends, technologies, strategies, alternative animal models, impeded vaccines4th (2001), 5th (2002), 10th (2006), 13th (2011), 15th (2012), 16th (2013), 17th (2014), 18th (2005)Vaccine shortages and supply6th (2003), 8th (2005)Vactine shortages and comparative models of disease and protection, synergies with human vaccine development, One Health Veterinary vaccines for zoonotic disease, economically important food animals, conservation medicine, differentiating infected from5th (2002), 6th (2003), 9th (2006), 13th (2010), 15th (2012)		
Recently-licensed vaccines (human papillomavirus, rotavirus, 4-valent meningococcal, varicella-zoster)11th (2008)Regulation of vaccines, general, for public health emergencies, for adjuvants3rd (2000), 7th (2004), 17th (2014)Regulatory/Suppressor T cells6th (2003)Respiratory infection vaccines3rd (2000), 16th (2013)Rotavirus vaccines15th (2012)RSV vaccines6th (2003)SARS (severe acute respiratory syndrome)/coronavirus vaccines7th (2004)Sexually-transmitted disease vaccines3rd (2000)Therapeutic vaccines2nd (1999), 8th (2005)Tuberculosis vaccines2nd (1999), 8th (2005), 12th (2013), 14th (2011), 15th (2012), 16th (2013), vaccines, trends, technologies, strategies, alternative animal models, impeded vaccines4th (2001), 9th (2006), 12th (2009), 15th (2012), 16th (2013), 17th (2014), 18th (2015)Vaccine shortages and supply6th (2003), 8th (2005)Veterinary vaccines and comparative models of disease and protection, synergies with human vaccine development, One Health Veterinary vaccines for zoonotic diseases, economically important food animals, conservation medicine, differentiating infected from5th (2002), 6th (2003), 9th (2006), 13th (2010), 15th (2012)		
Regulation of vaccines, general, for public health emergencies, for adjuvants3rd (2000), 7th (2004), 17th (2014)Regulatory/Suppressor T cells6th (2003)Respiratory infection vaccines3rd (2000), 16th (2013)Rotavirus vaccines15th (2012)RSV vaccines6th (2003)SARS (severe acute respiratory syndrome)/coronavirus vaccines7th (2004)Sexually-transmitted disease vaccines3rd (2000)Therapeutic vaccines2nd (1999), 8th (2005)Tuberculosis vaccines2nd (1999), 9th (2006), 12th (2009), 16th (2013)Vaccine development: new and innovative approaches, immunogens, impeded vaccines4th (2001), 5th (2002), 10th (2006), 13th (2010), 14th (2011), 15th (2012), 16th (2013), 17th (2014), 18th (2015)Vaccine safety surveillance and research4th (2001), 9th (2006), 12th (2009), 15th (2012Vaccine shortages and supply6th (2003), 8th (2005)Veterinary vaccines and comparative models of disease and protection, synergies with human vaccine development, One Health Veterinary vaccines for zoonotic diseases, economically importent food animals, conservation medicine, differentiating infected from5th (2002), 6th (2003), 9th (2006), 13th (2010), 15th (2012)	Recently-licensed vaccines (human papillomavirus, rotavirus, 4-valent	
adjuvantsConstruction for the formation of the fo		
Regulatory/Suppressor T cells6th (2003)Respiratory infection vaccines3rd (2000), 16th (2013)Rotavirus vaccines15th (2012)RSV vaccines6th (2003)SARS (severe acute respiratory syndrome)/coronavirus vaccines7th (2004)Sexually-transmitted disease vaccines3rd (2000)Therapeutic vaccines2nd (1999), 8th (2005)Tuberculosis vaccines2nd (1999), 9th (2006), 12th (2009), 16th (2013)Vaccine development: new and innovative approaches, immunogens, waccines, trends, technologies, strategies, alternative animal models, impeded vaccines17th (2014), 18th (2015)Vaccine safety surveillance and research4th (2001), 9th (2006), 12th (2009), 15th (2012)Vaccine shortages and supply6th (2003), 8th (2005)Veterinary vaccines for zoonotic diseases, economically important food animals, conservation medicine, differentiating infected from5th (2002), 6th (2003), 9th (2006), 13th (2010), 15th (2012)		3rd (2000), 7th (2004), 17th (2014)
Respiratory infection vaccines3rd (2000), 16th (2013)Rotavirus vaccines15th (2012)RSV vaccines6th (2003)SARS (severe acute respiratory syndrome)/coronavirus vaccines7th (2004)Sexually-transmitted disease vaccines3rd (2000)Therapeutic vaccines2nd (1999), 8th (2005)Tuberculosis vaccines2nd (1999), 9th (2006), 12th (2009), 16th (2013)Vaccine development: new and innovative approaches, immunogens, vaccines, trends, technologies, strategies, alternative animal models, impeded vaccines17th (2011), 5th (2002), 10th (2006), 13th (2010), 14th (2011), 15th (2012), 16th (2013), 17th (2011), 9th (2006), 12th (2009), 15th (2012Vaccine safety surveillance and research4th (2001), 9th (2006), 12th (2009), 15th (2012Vaccine shortages and supply6th (2003), 8th (2005)Veterinary vaccines and comparative models of disease and protection, synergies with human vaccine development, One Health Veterinary vaccines for zoonotic diseases, economically important food animals, conservation medicine, differentiating infected from5th (2002), 6th (2003), 9th (2006), 13th (2010), 15th (2012)	•	6th (2002)
Rotavirus vaccines15th (2012)RSV vaccines6th (2003)SARS (severe acute respiratory syndrome)/coronavirus vaccines7th (2004)Sexually-transmitted disease vaccines3rd (2000)Therapeutic vaccines2nd (1999), 8th (2005)Tuberculosis vaccines2nd (1999), 9th (2006), 12th (2009), 16th (2013)Vaccine development: new and innovative approaches, immunogens, vaccines, trends, technologies, strategies, alternative animal models, impeded vaccines17th (2001), 5th (2002), 10th (2006), 13th (2010), 14th (2011), 15th (2012), 16th (2013), 17th (2014), 18th (2015)Vaccine safety surveillance and research4th (2001), 9th (2006), 12th (2009), 15th (2012 6th (2003), 8th (2005)Veterinary vaccines and comparative models of disease and protection, synergies with human vaccine development, One Health Veterinary vaccines for zoonotic diseases, economically important food animals, conservation medicine, differentiating infected from5th (2002), 6th (2003), 9th (2006), 13th (2010), 15th (2012)		
SARS (severe acute respiratory syndrome)/coronavirus vaccines7th (2004)Sexually-transmitted disease vaccines3rd (2000)Therapeutic vaccines2nd (1999), 8th (2005)Tuberculosis vaccines2nd (1999), 9th (2006), 12th (2009), 16th (2013)Vaccine development: new and innovative approaches, immunogens, vaccines, trends, technologies, strategies, alternative animal models, impeded vaccines17th (2011), 15th (2012), 16th (2013), 17th (2014), 18th (2015)Vaccine safety surveillance and research4th (2001), 9th (2006), 12th (2009), 15th (2012Vaccine shortages and supply6th (2003), 8th (2005)Veterinary vaccines and comparative models of disease and protection, synergies with human vaccine development, One Health Veterinary vaccines for zoonotic diseases, economically important food animals, conservation medicine, differentiating infected from5th (2002), 6th (2003), 9th (2006), 13th (2010), 15th (2012)		
Sexually-transmitted disease vaccines3rd (2000)Therapeutic vaccines2nd (1999), 8th (2005)Tuberculosis vaccines2nd (1999), 9th (2006), 12th (2009), 16th (2013)Vaccine development: new and innovative approaches, immunogens, vaccines, trends, technologies, strategies, alternative animal models, impeded vaccines2nd (1999), 9th (2006), 12th (2009), 16th (2013)Vaccine safety surveillance and research4th (2001), 5th (2012), 10th (2006), 13th (2010), 14th (2011), 15th (2012), 16th (2013), 17th (2014), 18th (2005)Vaccine shortages and supply6th (2003), 8th (2005)Veterinary vaccines and comparative models of disease and protection, synergies with human vaccine development, One Health Veterinary vaccines for zoonotic diseases, economically important food animals, conservation medicine, differentiating infected from5th (2002), 6th (2003), 9th (2006), 13th (2010), 15th (2012)	RSV vaccines	6th (2003)
Therapeutic vaccines2nd (1999), 8th (2005)Tuberculosis vaccines2nd (1999), 9th (2006), 12th (2009), 16th (2013)Vaccine development: new and innovative approaches, immunogens, vaccines, trends, technologies, strategies, alternative animal models, impeded vaccines4th (2001), 5th (2002), 10th (2006), 13th (2010), 14th (2011), 15th (2012), 16th (2013), 17th (2014), 18th (2015)Vaccine safety surveillance and research4th (2001), 9th (2006), 12th (2009), 15th (2012Vaccine shortages and supply6th (2003), 8th (2005)Veterinary vaccines and comparative models of disease and protection, synergies with human vaccine development, One Health Veterinary vaccines for zoonotic diseases, economically important food animals, conservation medicine, differentiating infected from5th (2002), 6th (2003), 9th (2006), 13th (2010), 15th (2012)		
Tuberculosis vaccines2nd (1999), 9th (2006), 12th (2009), 16th (2013)Vaccine development: new and innovative approaches, immunogens, vaccines, trends, technologies, strategies, alternative animal models, impeded vaccines2nd (1999), 9th (2006), 12th (2009), 16th (2013)Vaccine safety surveillance and research4th (2001), 5th (2002), 10th (2006), 13th (2010), 14th (2011), 15th (2012), 16th (2013), 17th (2014), 18th (2015)Vaccine shortages and supply4th (2001), 9th (2006), 12th (2009), 15th (2012Veterinary vaccines and comparative models of disease and protection, synergies with human vaccine development, One Health Veterinary vaccines for zoonotic diseases, economically important food animals, conservation medicine, differentiating infected from5th (2002), 6th (2003), 9th (2006), 13th (2010), 15th (2012)		
Vaccine development: new and innovative approaches, immunogens, vaccines, trends, technologies, strategies, alternative animal models, impeded vaccines4th (2001), 5th (2002), 10th (2006), 13th (2010), 14th (2011), 15th (2012), 16th (2013), 17th (2014), 18th (2015)Vaccine safety surveillance and research Vaccine shortages and supply4th (2001), 9th (2006), 12th (2009), 15th (2012 6th (2003), 8th (2005)Veterinary vaccines and comparative models of disease and protection, synergies with human vaccine development, One Health Veterinary vaccines for zoonotic diseases, economically important food animals, conservation medicine, differentiating infected from5th (2002), 6th (2003), 9th (2006), 13th (2010), 15th (2012)		
vaccines, trends, technologies, strategies, alternative animal models, impeded vaccines17th (2014), 18th (2015)Vaccine safety surveillance and research4th (2001), 9th (2006), 12th (2009), 15th (2012Vaccine shortages and supply6th (2003), 8th (2005)Veterinary vaccines and comparative models of disease and protection, synergies with human vaccine development, One Health1st (1998), 12th (2009), 14th (2011)Veterinary vaccines for zoonotic diseases, economically important food animals, conservation medicine, differentiating infected from5th (2002), 6th (2003), 9th (2006), 13th (2010), 15th (2012)		
impeded vaccines4th (2001), 9th (2006), 12th (2009), 15th (2012Vaccine safety surveillance and research4th (2001), 9th (2006), 12th (2009), 15th (2012Vaccine shortages and supply6th (2003), 8th (2005)Veterinary vaccines and comparative models of disease and protection, synergies with human vaccine development, One Health Veterinary vaccines for zoonotic diseases, economically important food animals, conservation medicine, differentiating infected from5th (2002), 6th (2003), 9th (2006), 13th (2010), 15th (2012)		
Vaccine shortages and supply6th (2003), 8th (2005)Veterinary vaccines and comparative models of disease and protection, synergies with human vaccine development, One Health Veterinary vaccines for zoonotic diseases, economically important food animals, conservation medicine, differentiating infected from6th (2003), 8th (2005)1st (1998), 12th (2009), 14th (2011)5th (2002), 6th (2003), 9th (2006), 13th (2010), 15th (2012)	impeded vaccines	
Veterinary vaccines and comparative models of disease and protection, synergies with human vaccine development, One Health Veterinary vaccines for zoonotic diseases, economically important food animals, conservation medicine, differentiating infected from1st (1998), 12th (2009), 14th (2011)5th (2002), 6th (2003), 9th (2006), 13th (2010), 15th (2012)		
protection, synergies with human vaccine development, One Health Veterinary vaccines for zoonotic diseases, economically important food animals, conservation medicine, differentiating infected from		
Veterinary vaccines for zoonotic diseases, economically important food animals, conservation medicine, differentiating infected from 5th (2002), 6th (2003), 9th (2006), 13th (2010), 15th (2012)	•	15t (1990), 12til (2009), 14til (2011)
food animals, conservation medicine, differentiating infected from		5th (2002), 6th (2003), 9th (2006), 13th (2010), 15th (2012)
vaccinated animals		
	vaccinated animals	

Diseases. These symposia included more than 20 presentations by leaders in their respective fields, on a large range of vaccine-related topics including talks on Group A Streptococcal vaccines, Therapeutic Vaccines against Alzheimer's Disease, Dengue Vaccines, Regulatory Considerations in Vaccine Effectiveness Evaluation, HIV1 Vaccine Progress, and Curative Potential of T Cell Transfer Immunotherapy for Cancer. In addition to the invited talks, there were 33 selected presentations from submitted abstracts covering an extensive array of vaccinology related topics in sessions ranging from the science of immune responses, preclinical and clinical studies of a variety of vaccines, vaccine effectiveness in disease prevention, vaccine safety and public perception, vaccine design, and vaccine administration and policy. The 2015 Charles Mérieux lecture honored Dr. D.A. Henderson for his many contributions to controlling/eradicating vaccine-preventable diseases including his leadership of the smallpox eradication program, while at the World Health Organization. Other awardees included Dr. Matt Moore, who presented the Robert Austrian Memorial Lecture entitled "Preventing Pediatric Pneumonia around the World: Challenges and Opportunities" and Jesse Erasmus, the Hilleman Awardee, who discussed "Development of the Eilat Virus, a Host-Restricted Alphavirus, as a Vaccine Platform". A closing Panel Discussion also covered Updates on Ebola Vaccines in Development.

This special section of Vaccine includes articles based on a subset of the invited presentations at the conference, and covers widely divergent themes within vaccinology. Dr. Christopher Broder et al. [4], assemble an overview of the epidemiologic rationale and current status of Nipah/Hendra Virus Animal Vaccines. This includes a description of the pioneering work from his lab to develop both a highly effective subunit vaccine based on the surface glycoprotein, as well as a promising monoclonal antibody against this protein that could be used for passive transfer immunoprophylaxis. Dr. Barney Graham [5] provides a comprehensive summary of new generation vaccines against Respiratory Syncytial Virus; a major childhood illness for which vaccine development has proven challenging. As part of this review of the field, he also summarizes some of the groundbreaking work from his group at the NIH Vaccine Research Center to elucidate the protective immune responses to the RSV surface fusion (F) glycoprotein, as well as the generation of a soluble molecularly stabilized pre-fusion form of this protein. Dr. Clifford Snapper [6] highlights work from over two decades of research efforts in his lab to decipher the immune responses to S. pneumoniae capsular polysaccharides, including a description of some of the critical determinants required for induction of antipolysaccharide antibodies. Finally, Dr. Peter Hotez and colleagues [7] detail the impetus and rationale for vaccines to control infections with helminths in the developing world; a major cause of disability and despair in populations where these pathogens are endemic.

References

- Breman JG, Arita I. The confirmation and maintenance of smallpox eradication. N Engl J Med 1980;303:1263–73.
- [2] Garon J, Seib K, Orenstein WA, Ramirez Gonzalez A, Chang Blanc D, Zaffran M, et al. Polio endgame: the global switch from tOPV to bOPV. Expert Rev Vaccines 2016:1–16.
- [3] Zhou F, Shefer A, Wenger J, Messonnier M, Wang LY, Lopez A, et al. Economic evaluation of the routine childhood immunization program in the United States, 2009. Pediatrics 2014;133:577–85.
- [4] Broder CC, Weir DL, Reid PA. Hendra virus and Nipah virus animal vaccines. Vaccine 2016;34:3525–34.
- [5] Graham BS. Vaccines against respiratory syncytial virus: The time has finally come. Vaccine 2016;34:3535–41.
- [6] Snapper CM. Differential regulation of polysaccharide-specific antibody responses to isolated polysaccharides, conjugate vaccines, and intact Grampositive versus Gram-negative extracellular bacteria. Vaccine 2016;34:3542–8.
- [7] Hotez PJ, Strych U, Lustigman S, Bottazzia ME. Human anthelminthic vaccines: Rationale and challenges. Vaccine 2016;34:3549–55.

Walter A. Orenstein^{a,b,1}

 ^a Emory Vaccine Center, Division of Infectious Diseases, Emory University School of Medicine, Atlanta, GA, United States
^b Department of Medicine, Division of Infectious Diseases, Emory University School of Medicine, Atlanta, GA, United States

Special Section Guest Editor Raphael Simon ^{a,b,*,2} ^a Center for Vaccine Development, Baltimore, MD, United States ^b University of Maryland School of Medicine, Baltimore, MD, United States

* Corresponding author at: Center for Vaccine Development, University of Maryland School of Medicine, HSF1 480, 685 West Baltimore St, Baltimore, MD, 21201 United States. *E-mail address:* rsimon@medicine.umaryland.edu (R. Simon)

¹ President, National Foundation for Infectious Diseases.

² Scientific and Organizing committee, National Foundation for Infectious Diseases Annual Conference on Vaccine Research.

Available online 4 May 2016